Gemcitabine and nab-paclitaxel combination (Gem/nab-P)

The combination of gemcitabine and nab-paclitaxel is a standard-of-care chemotherapy regimen primarily utilized for the treatment of metastatic pancreatic adenocarcinoma. Gemcitabine is a pyrimidine nucleoside analog that functions as an antimetabolite to disrupt DNA synthesis, while nab-paclitaxel is an albumin-bound formulation of paclitaxel that acts as a microtubule-stabilizing agent to induce mitotic arrest. Preclinical and clinical evidence suggests a synergistic relationship where nab-paclitaxel enhances the delivery and efficacy of gemcitabine by altering the tumor microenvironment and inhibiting gemcitabine-degrading enzymes. This regimen was established as a first-line treatment following the landmark MPACT trial, which demonstrated significant improvements in overall survival compared to gemcitabine monotherapy. While effective, the combination is associated with cumulative toxicities, including significant myelosuppression and peripheral neuropathy.

Other names

Gem/nab-PGNPGem/AbraxaneGemcitabine plus albumin-bound paclitaxel

Gemcitabine inhibits DNA synthesis by replacing cytidine during replication and inhibiting ribonucleotide reductase. Nab-paclitaxel promotes microtubule assembly and prevents disassembly, leading to cell cycle arrest. The combination is synergistic; nab-paclitaxel reduces levels of cytidine deaminase, the primary enzyme responsible for gemcitabine degradation, thereby increasing intratumoral gemcitabine concentrations (Frese KK, et al., Cancer Discov. 2012). Additionally, nab-paclitaxel may enhance gemcitabine delivery by depleting the dense desmoplastic stroma characteristic of pancreatic tumors (Neesse A, et al., Gut. 2011).